The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is ...

Researchers at Case Western Reserve school of Medicine looked at nearly one million patients in the U.S. with Type 2 diabetes ...

CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to ...

Galantamine slowed decline in cognitive function, functional ability, and behavior at 6 months in people with Alzheimer's ...

When you find as a loved one, having to be in those difficult conversations, or to try to make her do things that she wasn't ...

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash positio ...

Shares of Acumen Pharmaceuticals fell after its loss widened and results missed analyst expectations in the third quarter. The stock fell 16% to $2.69 in afternoon trading Tuesday. Shares, which had ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

Under Armour Inc. Cl C 0.00% $3.94B Under Armour Inc. Cl A-0.10% $3.94B ...